Innate Pharma S.A.
IPH.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.37 | -0.01 | 0.01 |
| FCF Yield | -24.06% | -8.54% | 2.28% | -13.24% |
| EV / EBITDA | -4.11 | -3.57 | -3.37 | -12.40 |
| Quality | ||||
| ROIC | -35.10% | -24.98% | -21.53% | -7.99% |
| Gross Margin | -322.22% | -194.55% | -135.53% | -14.58% |
| Cash Conversion Ratio | 1.46 | 0.40 | -0.12 | 2.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.93% | -16.63% | -24.04% | -13.25% |
| Free Cash Flow Growth | -210.98% | -464.69% | 113.03% | -79.46% |
| Safety | ||||
| Net Debt / EBITDA | 1.06 | 1.54 | 1.35 | 2.95 |
| Interest Coverage | -111.03 | -6.87 | -43.86 | -4.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -13.24 | -5.35 | -24.22 | 163.76 |